search
Back to results

Safety Study of Deep Brain Stimulation to Manage Thalamic Pain Syndrome (DBS)

Primary Purpose

Chronic Pain

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Deep Brain Stimulation for Thalamic Pain Syndrome
Sponsored by
Andre Machado
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Pain

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of thalamic pain syndrome
  • with allodynia or dysesthesia
  • with pinprick anesthesia or hypoesthesia on the affected hemibody (anesthesia dolorosa).
  • Six months or more of medically refractory severe pain (see below).
  • Pain disability reported by the pain index >30 points at the time of enrollment.
  • Average daily pain for the past 30 days reported as >5 on a 0-10 scale
  • Failure to respond adequately to at least one antidepressant, one anti-seizure medication and one oral narcotic.
  • MRI done within one year of the first visit showing a lesion that involves the posterior thalamic region or a lesion in the dorsal or ventral vicinity of the thalamus (i.e. semi oval white matter or brain stem). The lesion will be contralateral to the hemibody affected by chronic pain or will involve cortical-subcortical areas in topography consistent with sensory thalamocortical connections. This will include patients with infarcts in the territory of the middle cerebral artery. A more recent MRI may be required if the patient's condition changed within the previous year.
  • Capable of understanding and providing informed consent
  • Age ≥ 21 years
  • Women of childbearing age must be on regular use of an accepted contraceptive method(s).
  • Previous surgical procedures: Patients with severe and refractory thalamic pain syndrome may have undergone other interventional or surgical procedures, as an attempt to alleviate the thalamic pain syndrome. Surgical procedure may include blocks, spinal cord stimulation, thalamic DBS, posterior limb of the internal capsule DBS or periaqueductal gray / periventricular gray DBS, cortical stimulation, peripheral ablative procedures or cerebral ablative procedures. In this study, patients with previously implanted cortical stimulation systems, or spinal and peripheral nervous system stimulation systems may be included. However, patients with previous motor cortex stimulation must have had the cortical stimulation system before being considered a candidate for this protocol. Removal of the cortical stimulation system will not be covered under this protocol. Patients with spinal or peripheral neuromodulation system may be included in the research provided that the implanted systems are compatible with the all research protocols (including fMRI) to be performed during the research. Patients with pervious DBS implants will not be considered candidates.

Exclusion Criteria:

  • Not capable of understanding or providing informed consent.
  • Aphasia severe enough to limit the consent process or communication between the investigators and the patient. Patients with mild or recovering aphasia may be considered candidates at the discretion of the PI.
  • Coagulopathy. Patients will be excluded unless assessed and cleared by hematology
  • Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery. Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation / antiaggregation therapy discontinuation.
  • Uncontrolled hypertension.
  • Malignancy with < 5 years life expectancy.
  • Major medical co-morbidities: end stage renal failure, heart failure, severe congestive heart disease, severe respiratory problems, liver failure or other significant medical co morbidities.
  • Major neurological disorder other than the one that led to the TPS.
  • MRI (done within one year of the first visit) with abnormalities other than those associated with the neurological disorder causing TPS.
  • Age < 21 years.
  • Pregnancy or lack of regular use of contraceptives. Patients who become pregnant after enrollment may be excluded from the study. Patients who become pregnant prior to the surgical implantation of the DBS systems will be excluded from the study.
  • Previous ablative intracranial surgery for the management of the TPS.
  • Previously implanted with deep brain stimulation system.
  • Concurrent enrolment in any other trial / study for TPS.
  • Implantable hardware not compatible with MRI or with the study.
  • Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from VC/VS DBS.
  • Untreated / uncontrolled (severe at the time of enrolment) depression or other psychiatric disorder.
  • Bipolar disorder, current PTSD, severe personality disorder, active psychosis, Severe OCD.
  • Psychological co-morbidities that indicates higher risk to the patient and / or higher risk of failure.
  • Suicide attempt </= 12 months
  • Communication of a plan for suicide, prior to implant, should the study treatment fail
  • Imminent suicide risk

Sites / Locations

  • Cleveland Clinic Foundation

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Treatment group

Control group

Arm Description

Active stimulation and programmed to the settings found to be optimal during the titration process.

IPG is set to ON but the voltage is set to 0V.

Outcomes

Primary Outcome Measures

Number of Participants With 50% Improvement in Pain Related Disability (as Assessed by the Pain Disability Index)
Pain Disability Index (PDI) directly measures disability related to the main components of daily life function and has been validated for thalamic pain syndrome. Range is 0 (no disability) to 10 (worst disability). The components are Family/Home Responsibilities, Recreation, Social Activity, Sexual Behavior, Life-support Activity, Occupation, & Self-care. This is an average score of the 3 month period for each Active and Sham phase.

Secondary Outcome Measures

Number of Participants Who Had 50% Improvement in PDI
A 50% improvement in pain related disability (as assessed by the pain disability index) at the end of the open label phase compared to the pre-implantation baseline. The PDI ranges from 0-10 with 0 equaling no disability and 10 equaling worst disability.
Number of Participants Who Would Undergo the Procedure Again.
A positive answer from patients receiving active stimulation at the end of the open label phase of the study to the question: 'would you undergo this procedure again if you were to get the same benefits you experienced?'
Number of Patient Who Had >50% Reduction in VAS.
Patients report reduction in the VAS (Visual Analogue Scale Ranging from 0-10, 0 meaning no pain and 10 meaning worst pain imaginable) at the end of the open label phase (24 months post randomization f/u) compared to the pre-implantation baseline.

Full Information

First Posted
February 19, 2010
Last Updated
May 1, 2017
Sponsor
Andre Machado
Collaborators
National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT01072656
Brief Title
Safety Study of Deep Brain Stimulation to Manage Thalamic Pain Syndrome
Acronym
DBS
Official Title
Deep Brain Stimulation for Thalamic Pain Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
May 2010 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Andre Machado
Collaborators
National Institutes of Health (NIH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the safety and efficacy of Deep Brian Stimulation (DBS) of the ventral capsular/ventral striatal as a treatment for patients with Thalamic Pain Syndrome (TPS). The central hypothesis to be tested in this investigation is that VC/VS stimulation will modulate the affective component of TPS and, consequently, improve pain related disability.
Detailed Description
This is a pilot clinical study of the therapeutic benefits of ventral capsular/ventral striatal deep brain stimulation (DBS) as a treatment for 10 patients with medically refractory thalamic pain syndrome. Patients to be enrolled under this protocol will have experienced severe pain for more than six months and will be considered medically refractory. Study subjects may have undergone and failed other surgical procedures or interventional procedures. Study subjects will have chronic, medically refractory pain of disabling severity, refractory to treatment attempts with conventional medications. Patients that are enrolled in the study will have bilateral DBS surgery, with implantation of one Medtronic 3391 DBS lead on either side of the brain. These leads will then be connected at first to a single Medtronic PC pulse generator to be implanted in the infraclavicular region on one side. Once the PC pulse generator is depleted, and the patient has completed the blinded phase of the study, the PC pulse generator will be replaced for an RC pulse generator. The RC pulse generator has a battery life of 9 years and is a good option for the open label phase and for continued stimulation after the study is completed. However, the RC is not ideal for the blinded phase because patients may be able to tell if they are receiving active or sham stimulation. For this reason, patients enrolled in this study will receive, initially, the implant with the PC generator. Patients will have at least 6 months of stable chronic pain associated with TPS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment group
Arm Type
Active Comparator
Arm Description
Active stimulation and programmed to the settings found to be optimal during the titration process.
Arm Title
Control group
Arm Type
Sham Comparator
Arm Description
IPG is set to ON but the voltage is set to 0V.
Intervention Type
Device
Intervention Name(s)
Deep Brain Stimulation for Thalamic Pain Syndrome
Intervention Description
Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
Primary Outcome Measure Information:
Title
Number of Participants With 50% Improvement in Pain Related Disability (as Assessed by the Pain Disability Index)
Description
Pain Disability Index (PDI) directly measures disability related to the main components of daily life function and has been validated for thalamic pain syndrome. Range is 0 (no disability) to 10 (worst disability). The components are Family/Home Responsibilities, Recreation, Social Activity, Sexual Behavior, Life-support Activity, Occupation, & Self-care. This is an average score of the 3 month period for each Active and Sham phase.
Time Frame
Blinded stimulation phase (3 Months)
Secondary Outcome Measure Information:
Title
Number of Participants Who Had 50% Improvement in PDI
Description
A 50% improvement in pain related disability (as assessed by the pain disability index) at the end of the open label phase compared to the pre-implantation baseline. The PDI ranges from 0-10 with 0 equaling no disability and 10 equaling worst disability.
Time Frame
24 months post randomization follow up
Title
Number of Participants Who Would Undergo the Procedure Again.
Description
A positive answer from patients receiving active stimulation at the end of the open label phase of the study to the question: 'would you undergo this procedure again if you were to get the same benefits you experienced?'
Time Frame
End of Open Label Phase (24 months)
Title
Number of Patient Who Had >50% Reduction in VAS.
Description
Patients report reduction in the VAS (Visual Analogue Scale Ranging from 0-10, 0 meaning no pain and 10 meaning worst pain imaginable) at the end of the open label phase (24 months post randomization f/u) compared to the pre-implantation baseline.
Time Frame
Baseline and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of thalamic pain syndrome with allodynia or dysesthesia with pinprick anesthesia or hypoesthesia on the affected hemibody (anesthesia dolorosa). Six months or more of medically refractory severe pain (see below). Pain disability reported by the pain index >30 points at the time of enrollment. Average daily pain for the past 30 days reported as >5 on a 0-10 scale Failure to respond adequately to at least one antidepressant, one anti-seizure medication and one oral narcotic. MRI done within one year of the first visit showing a lesion that involves the posterior thalamic region or a lesion in the dorsal or ventral vicinity of the thalamus (i.e. semi oval white matter or brain stem). The lesion will be contralateral to the hemibody affected by chronic pain or will involve cortical-subcortical areas in topography consistent with sensory thalamocortical connections. This will include patients with infarcts in the territory of the middle cerebral artery. A more recent MRI may be required if the patient's condition changed within the previous year. Capable of understanding and providing informed consent Age ≥ 21 years Women of childbearing age must be on regular use of an accepted contraceptive method(s). Previous surgical procedures: Patients with severe and refractory thalamic pain syndrome may have undergone other interventional or surgical procedures, as an attempt to alleviate the thalamic pain syndrome. Surgical procedure may include blocks, spinal cord stimulation, thalamic DBS, posterior limb of the internal capsule DBS or periaqueductal gray / periventricular gray DBS, cortical stimulation, peripheral ablative procedures or cerebral ablative procedures. In this study, patients with previously implanted cortical stimulation systems, or spinal and peripheral nervous system stimulation systems may be included. However, patients with previous motor cortex stimulation must have had the cortical stimulation system before being considered a candidate for this protocol. Removal of the cortical stimulation system will not be covered under this protocol. Patients with spinal or peripheral neuromodulation system may be included in the research provided that the implanted systems are compatible with the all research protocols (including fMRI) to be performed during the research. Patients with pervious DBS implants will not be considered candidates. Exclusion Criteria: Not capable of understanding or providing informed consent. Aphasia severe enough to limit the consent process or communication between the investigators and the patient. Patients with mild or recovering aphasia may be considered candidates at the discretion of the PI. Coagulopathy. Patients will be excluded unless assessed and cleared by hematology Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery. Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation / antiaggregation therapy discontinuation. Uncontrolled hypertension. Malignancy with < 5 years life expectancy. Major medical co-morbidities: end stage renal failure, heart failure, severe congestive heart disease, severe respiratory problems, liver failure or other significant medical co morbidities. Major neurological disorder other than the one that led to the TPS. MRI (done within one year of the first visit) with abnormalities other than those associated with the neurological disorder causing TPS. Age < 21 years. Pregnancy or lack of regular use of contraceptives. Patients who become pregnant after enrollment may be excluded from the study. Patients who become pregnant prior to the surgical implantation of the DBS systems will be excluded from the study. Previous ablative intracranial surgery for the management of the TPS. Previously implanted with deep brain stimulation system. Concurrent enrolment in any other trial / study for TPS. Implantable hardware not compatible with MRI or with the study. Patients may be excluded from enrollment due to a condition that, in the judgment of the PI, significantly increases risk or reduces significantly the likelihood of benefit from VC/VS DBS. Untreated / uncontrolled (severe at the time of enrolment) depression or other psychiatric disorder. Bipolar disorder, current PTSD, severe personality disorder, active psychosis, Severe OCD. Psychological co-morbidities that indicates higher risk to the patient and / or higher risk of failure. Suicide attempt </= 12 months Communication of a plan for suicide, prior to implant, should the study treatment fail Imminent suicide risk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andre G Machado, MD
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
27358316
Citation
Gopalakrishnan R, Burgess RC, Lempka SF, Gale JT, Floden DP, Machado AG. Pain anticipatory phenomena in patients with central poststroke pain: a magnetoencephalography study. J Neurophysiol. 2016 Sep 1;116(3):1387-95. doi: 10.1152/jn.00215.2016. Epub 2016 Jun 29.
Results Reference
background
PubMed Identifier
26733321
Citation
Gopalakrishnan R, Burgess RC, Plow EB, Floden DP, Machado AG. Early event related fields during visually evoked pain anticipation. Clin Neurophysiol. 2016 Mar;127(3):1855-63. doi: 10.1016/j.clinph.2015.11.019. Epub 2015 Dec 5.
Results Reference
background
PubMed Identifier
23902631
Citation
Plow EB, Malone DA Jr, Machado A. Deep brain stimulation of the ventral striatum/anterior limb of the internal capsule in thalamic pain syndrome: study protocol for a pilot randomized controlled trial. Trials. 2013 Jul 31;14:241. doi: 10.1186/1745-6215-14-241.
Results Reference
derived

Learn more about this trial

Safety Study of Deep Brain Stimulation to Manage Thalamic Pain Syndrome

We'll reach out to this number within 24 hrs